Ion endoluminal system
Ion procedures grew about 36% in Q2 2026, and 55 Ion systems were placed in the quarter.
The numbers
What it is
Ion is a robotic platform for minimally invasive lung biopsies through the airways. It is a smaller business than da Vinci but is growing faster, and it adds consumables revenue with each procedure.
Why it matters to the stock. Ion is the fastest-growing procedure line in the portfolio, so it is a second source of recurring instrument revenue.
News
Intuitive sets 2026 da Vinci procedure growth guide at 13.5% to 15.5%
For full-year 2026, Intuitive expects da Vinci procedure growth of about 13.5% to 15.5%, with the company expecting to land closer to the midpoint.
Taylor Patton named Chief Commercial and Marketing Officer effective July 1
Intuitive appointed Taylor Patton, previously global senior vice president of its endoluminal business, as chief commercial and marketing officer effective July 1, 2026.
Intuitive Q1 2026 revenue up 23% to $2.77 billion; raises 2026 procedure and margin guidance
Intuitive reported first-quarter 2026 revenue of $2.77 billion, up 23%, with non-GAAP EPS of $2.50 and GAAP EPS of $2.28.
Intuitive completes purchase of da Vinci and Ion distributors in Italy, Spain and Portugal
Intuitive completed its acquisition of the da Vinci and Ion distribution business run by ab medica, Abex and Excelencia Robótica.
Intuitive gives preliminary Q4 and full-year 2025 results ahead of JPMorgan conference
Intuitive released preliminary fourth-quarter and full-year 2025 figures on January 14, 2026, the day of its J.P.